Industries > Pharma > Global Diabetes Drugs Market 2017-2027

Global Diabetes Drugs Market 2017-2027

Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others

PUBLISHED: 27 July 2017
PAGES: 262
PRODUCT CODE: PHA0218
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0218 Categories: , Tag:

The global diabetes drugs market was valued at $49.26bn in 2016 and is projected to grow at a CAGR of 6.1% in the first half of the forecast period.to reach global revenue of $66.29bn in 2021. The largest drug class in the market in 2016 was human insulin and analogues. This drug class held 55% share of the global diabetes drugs market in 2016.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new 262 page report you will receive 75 tables and 141 figures – all unavailable elsewhere.

The 262-page report provides clear detailed insight into the global diabetes drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Diabetes Drugs Market forecasts from 2017-2027

• Provides qualitative analysis and forecast of the human insulins and analogues submarket for the period 2017-2027:
• Lantus (insulin aspart)
• NovoLog (insulin aspart)
• Humalog (insulin lispro)
• Levemir (insulin detemir)
• Human Insulins by Novo Nordisk
• NovoMix (insulin aspart)
• Humulin (insulin isophane)

• Provides qualitative analysis and forecast of the dipeptidyl peptidase-4 inhibitors (DPP-4) submarket for the period 2017-2027:
• Januvia (sitagliptin)
• Janumet (sitagliptin and metformin)
• Galvus (vidagliptin)
• Onglyza (saxagluiptin)
• Nesina (alogliptin)
• Tradjenta (linagliptin)

• Provides qualitative analysis and forecast of the sulfonylurea submarket for the period 2017-2027:
• Diamicron (gliclazide)
• Amaryl (glimepiride)
• Glucotrol (glipizide)

• Provides qualitative analysis and forecast of the glucagon-like peptide-1 (GLP-1) receptor agonists submarket for the period 2017-2027:
• Victoza (liraglutide)
• Byetta (exenatide)
• Bydureon (exenatide)

• Provides qualitative analysis and forecast of the alpha-glucosidase class submarket for the period 2017-2027:
• Glucobay (acarbose)
• Basen (voglibose)
• Glyset (miglitol)

Global Diabetes Drugs Market 2017-2027

• Provides qualitative analysis and forecast of the meglitinides submarket for the period 2017-2027:

• Prandin (repaglinide)
• Sarlix (nateglinide)
• Glufast (acarbose).

• Provides qualitative analysis and forecast of the sodium-glucose co-transporter 2 (SGLT2) inhibitors submarket for the period 2017-2027:
• Invokana (canagliflozin)
• Forxiga (dapagliflozin)
• Jardiance (empaglifozin)

• Provides qualitative analysis and forecast of the biguanides submarket for the period 2017-2027:
• Glucophage (metformin)
• Glumetza (metformin)
• Fortamet (metformin)

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• United States
• Japan
• EU5 (Germany, France, UK, Italy, Spain)
• China
• India
• Russia
• Brazil

• This report discusses the SWOT and STEP Analysis of the global diabetes drugs market

• This report also discusses the diabetes R&D pipeline, recent approvals and summarizes anti-diabetes drug developments by Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca and others

Visiongain’s study is intended for anyone requiring commercial analyses for the global diabetes drugs market. You find data, trends and predictions.

Buy our report today Global Diabetes Drugs Market 2017-2027: Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Diabetes Drugs Market 2017-2027

    Download sample pages

    Complete the form below to download your free sample pages for Global Diabetes Drugs Market 2017-2027

      Latest Pharma news

      Visiongain Publishes Antibiotics Market Report 2023-2033

      The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Clinical Trial Supplies Market Report 2023-2033

      The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Meningococcal Vaccines Market Report 2023-2033

      The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Human Microbiome Market Report 2023-2033

      The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.

      30 January 2023

      READ